BTEC.L vs. GNOM.L
BTEC.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) and GNOM.L (Global X Genomics & Biotechnology UCITS ETF) are both Health & Biotech Equities funds - BTEC.L tracks the NASDAQ Biotechnology NET Index while GNOM.L tracks the Global X Genomics & Biotechnology UCITS ETF. Both are passively managed. Over the past 3 years, BTEC.L returned 16.99%/yr vs 4.58%/yr for GNOM.L. Their correlation of 0.84 suggests significant overlap in exposure. BTEC.L charges 0.35%/yr vs 0.50%/yr for GNOM.L.
Performance
BTEC.L vs. GNOM.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BTEC.L achieves a 15.22% return, which is significantly lower than GNOM.L's 22.10% return.
BTEC.L
- 1D
- 0.68%
- 1M
- 9.55%
- 6M
- 13.18%
- YTD
- 15.22%
- 1Y
- 50.31%
- 3Y*
- 16.99%
- 5Y*
- 5.87%
- 10Y*
- —
GNOM.L
- 1D
- -0.17%
- 1M
- 11.69%
- 6M
- 15.71%
- YTD
- 22.10%
- 1Y
- 62.79%
- 3Y*
- 4.58%
- 5Y*
- —
- 10Y*
- —
BTEC.L vs. GNOM.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 15.22% | 32.96% | -2.04% | 6.22% | -11.92% | -5.74% |
GNOM.L Global X Genomics & Biotechnology UCITS ETF | 22.10% | 19.30% | -17.99% | -5.77% | -37.21% | -8.59% |
Correlation
The correlation between BTEC.L and GNOM.L is 0.83, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.83 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.83 |
Correlation (All Time) Calculated using the full available price history since Nov 2, 2021 | 0.84 |
The correlation between BTEC.L and GNOM.L has been stable across timeframes, ranging from 0.83 to 0.84 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEC.L vs. GNOM.L — Risk / Return Rank
BTEC.L
GNOM.L
BTEC.L vs. GNOM.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) and Global X Genomics & Biotechnology UCITS ETF (GNOM.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BTEC.L | GNOM.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.30 | ||
| Sortino ratioReturn per unit of downside risk | +0.38 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.34 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 6.22 | 3.35 | +2.87 |
| Martin ratioReturn relative to average drawdown | 19.15 | 9.16 | +9.98 |
Loading charts...
Drawdowns
BTEC.L vs. GNOM.L - Drawdown Comparison
The maximum BTEC.L drawdown since its inception was -38.42%, smaller than the maximum GNOM.L drawdown of -69.32%. Use the drawdown chart below to compare losses from any high point for BTEC.L and GNOM.L.
Loading charts...
Drawdown Indicators
| BTEC.L | GNOM.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.42% | -69.32% | +30.90% |
Max Drawdown (1Y)Largest decline over 1 year | -7.94% | -18.91% | +10.97% |
Max Drawdown (3Y)Largest decline over 3 years | -26.74% | -44.77% | +18.03% |
Max Drawdown (5Y)Largest decline over 5 years | -38.42% | — | — |
Current DrawdownCurrent decline from peak | -3.87% | -37.11% | +33.24% |
Average DrawdownAverage peak-to-trough decline | -13.22% | -47.16% | +33.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.58% | 6.92% | -4.34% |
Volatility
BTEC.L vs. GNOM.L - Volatility Comparison
The current volatility for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) is 5.91%, while Global X Genomics & Biotechnology UCITS ETF (GNOM.L) has a volatility of 8.41%. This indicates that BTEC.L experiences smaller price fluctuations and is considered to be less risky than GNOM.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEC.L | GNOM.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.91% | 8.41% | -2.50% |
Volatility (6M)Calculated over the trailing 6-month period | 15.67% | 22.18% | -6.51% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.42% | 29.87% | -9.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.39% | 33.11% | -11.72% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.37% | 33.11% | -10.74% |
BTEC.L vs. GNOM.L - Expense Ratio Comparison
BTEC.L has a 0.35% expense ratio, which is lower than GNOM.L's 0.50% expense ratio.
Dividends
BTEC.L vs. GNOM.L - Dividend Comparison
Neither BTEC.L nor GNOM.L has paid dividends to shareholders.
Frequently Asked Questions
BTEC.L and GNOM.L have a correlation of 0.83, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BTEC.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BTEC.L is cheaper with a 0.35% expense ratio, compared with 0.50% for GNOM.L.
BTEC.L tracks NASDAQ Biotechnology NET Index, while GNOM.L tracks Global X Genomics & Biotechnology UCITS ETF. They also come from different issuers: iShares and Global X. Their fees differ too: 0.35% for BTEC.L and 0.50% for GNOM.L.
Find the right allocation for BTEC.L and GNOM.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer